Development of Outcome Measures for Large-vessel Vasculitis for Use in Clinical Trials: Opportunities, Challenges, and Research Agenda
Open Access
- 1 July 2011
- journal article
- review article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 38 (7), 1471-1479
- https://doi.org/10.3899/jrheum.110275
Abstract
Giant cell (GCA) and Takayasu’s arteritis (TAK) are 2 forms of large-vessel vasculitis (LVV) that involve the aorta and its major branches. GCA has a predilection for the cranial branches, while TAK tends to affect the extracranial branches. Both disorders may also cause nonspecific constitutional symptoms. Although some clinical features are more common in one or the other disorder and the ages of initial presentation differ substantially, there is enough clinical and histopathologic overlap between these disorders that some investigators suggest GCA and TAK may be 2 processes within the spectrum of a single disease. There have been few randomized therapeutic trials completed in GCA, and none in TAK. The lack of therapeutic trials in LVV is only partially explained by the rarity of these diseases. It is likely that the lack of well validated outcome measures for LVV and uncertainties regarding trial design contribute to the paucity of trials for these diseases. An initiative to develop a core set of outcome measures for use in clinical trials of LVV was launched by the international OMERACT Vasculitis Working Group in 2009 and subsequently endorsed by the OMERACT community at the OMERACT 10 meeting. Aims of this initiative include: (1) to review the literature and existing data related to outcome assessments in LVV; (2) to obtain the opinion of experts and patients on disease content; and (3) to formulate a research agenda to facilitate a more data-based approach to outcomes development.Keywords
This publication has 116 references indexed in Scilit:
- The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated VasculitisThe Journal of Rheumatology, 2011
- Patient‐reported outcome assessment in vasculitis may provide important data and a unique perspectiveArthritis Care & Research, 2010
- Assessment of disease activity and progression in Takayasu’s arteritis with Disease Extent Index-TakayasuRheumatology, 2010
- Circulation levels of acute phase proteins in patients with Takayasu arteritisJournal of Vascular Surgery, 2010
- Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9The Journal of Rheumatology, 2009
- Risk factors for cardiovascular disease and endothelin-1 levels in Takayasu arteritis patientsClinical Rheumatology, 2008
- Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-upAnnals Of The Rheumatic Diseases, 2008
- Quality of life of patients with Takayasu’s arteritisJournal of Vascular Surgery, 2008
- Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritisClinical Rheumatology, 2007
- Relationship between serum levels of macrophage migration inhibitory factor and the activity of antineutrophil cytoplasmic antibody-associated vasculitidesClinical Rheumatology, 2006